Business
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
LP-184 is the first of Lantern’s drug candidates developed by leveraging Lantern’s AI platform, RADR® US FDA previously granted LP-184 Rare Pediatric Disease
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nLP-184 is the first of Lantern’s drug candidates developed by leveraging Lantern’s AI platform, RADR®\n\n\n\nUS FDA previously granted LP-184 Rare Pediatric Disease Designation and Orphan Drug Designation (ODD) for the treatment of pediatric patients with ATRT\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (ML) platform with multiple clinical-stage drug programs, received a notice of allowance from the United States Patent and Trademark Office (USPTO) covering a method of treatment for Atypical Teratoid Rhabdoid Tumor (ATRT) using LP-184, an aggressive and rapidly growing form of cancer of the central nervous system (CNS).\n\n\n“This patent allowance further fortifies Lantern Pharma's intellectual property portfolio, providing us with an additional layer of protection for our potential blockbuster LP-184 program, which is being developed for multiple targeted oncology indications, including ATRT in pediatric patients,” said Panna Sharma, CEO of Lantern Pharma. “Historically, pediatric ATRT has been treated with a combination of surgery, radiation, and chemotherapy, but unfortunately, these approaches have often resulted in unfavorable long-term outcomes for the children affected.”\n\n\nDrs. Kosj and Jaymi Yamoah, Co-founders of Hope4ATRT, a research entity dedicated to directing resources and research to families in the fight against ATRT, commented, “As parents of a child who did not survive ATRT, we are compelled to advocate for more effective and less toxic treatment options for children still in this battle, and we are always thrilled to see progress in ATRT research. The work by Lantern scientists to rapidly develop new therapies with potential to treat ATRT brings us hope for the future.”\n\n\nSharma continued, “The urgent need for new treatment options for pediatric brain cancers cannot be overstated. Our in-silico and in-vivo observations indicate that LP-184 has the potential to become an essential part of the treatment options for these patients, and this patent allowance provides a further assurance of protection for our advances in the treatment of this devastating disease.”\n\n\nLP-184 is the first of Lantern’s drug candidates developed by lev...